HK Stock Market Move | PEGBIO CO-B(02565) rose more than 20% to hit a new high at the close. Recently granted exclusive license for diabetes drugs in the Middle East and Africa.

15:36 31/10/2025

PegBio Pharmaceutical-B (02565) soared more than 20% at the close, hitting a high of HK$62.25, setting a new record since its listing. As of the time of writing, it rose by 16.51% to HK$60.3, with a trading volume of HK$302.346 million.

PEGBIO CO-B(02565) rose more than 20% at the end of the day, reaching a high of 62.25 Hong Kong dollars, setting a new record high. As of the time of publication, it rose by 16.51%, to 60.3 Hong Kong dollars, with a trading volume of 30.2346 million Hong Kong dollars. On the news front, Pegbio Pharmaceuticals recently announced a strategic partnership with leading medical research institution PDC FZ-LLC in the UAE, granting exclusive rights to develop, distribute, market, and commercialize Pegbio's core product, Visepegenatide (PB-119), in the Middle East and Africa region. This collaboration marks a key step in Pegbio's global commercialization strategy. Visepegenatide (PB-119) is a weekly subcutaneous injection of GLP-1 receptor agonist developed by Pegbio for the treatment of type 2 diabetes and weight management. According to data from the International Diabetes Federation, the prevalence of diabetes in adults in the Middle East and North Africa is as high as 16.2%, ranking the highest globally. This collaboration is expected to accelerate the adoption of Visepegenatide (PB-119), offering innovative treatment to many underserved patients in the region.

Anhui Sunhere Pharmaceutical Excipients (300452.SZ) shareholder Shanghai Fosun Pharmaceutical plans to reduce its shareholding by no more than 3%.

DAIDO GROUP (00544) intends to offer a discount of approximately 2.44% on a total of 10 million subscribed shares, raising a net amount of approximately HK$19.72 million.

US Stock Market Move | Concept stocks related to AI applications collectively surged, with Twilio (TWLO.US) rising more than 15% after its earnings release.

Anhui Sunhere Pharmaceutical Excipients (300452.SZ) shareholder Shanghai Fosun Pharmaceutical plans to reduce its shareholding by no more than 3%.

DAIDO GROUP (00544) intends to offer a discount of approximately 2.44% on a total of 10 million subscribed shares, raising a net amount of approximately HK$19.72 million.

US Stock Market Move | Concept stocks related to AI applications collectively surged, with Twilio (TWLO.US) rising more than 15% after its earnings release.